摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cis-1-hydroxymethyl-2-methylcyclohexane | 3937-45-9

中文名称
——
中文别名
——
英文名称
cis-1-hydroxymethyl-2-methylcyclohexane
英文别名
[(1S*,2R*)-2-methylcyclohexyl]methanol;(+/-)-cis-2-Methyl-1-hydroxymethyl-cyclohexan;cis-2-Methyl-cyclohexanmethanol;(+/-)-(cis-2-Methyl-cyclohexyl)-methanol;(+/-)-2c-Methyl-1r-hydroxymethyl-cyclohexan;cis-2-methyl-cyclohexanemethanol;[(1R,2S)-2-methylcyclohexyl]methanol
cis-1-hydroxymethyl-2-methylcyclohexane化学式
CAS
3937-45-9
化学式
C8H16O
mdl
——
分子量
128.214
InChiKey
NIDINIHOPRFWFJ-YUMQZZPRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    188.5°C (estimate)
  • 密度:
    0.9342

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

SDS

SDS:4d6a9adf9a8c63c22f516d13f3fa6abc
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    某些含有环丙基甲基系统的基团的开环
    摘要:
    通过适当的卤化物与三苯基或三丁基锡烷的相互作用,容易产生含有环丙基甲基系统的单环和双环基团。每个被研究的基团都通过更取代的βγ键的裂变而开环。在第二自由基(12b)的情况下,优先以反式构型形成新的双键。无法通过此方法高精度确定的速率常数在1×10 7 –3×10 8 s –1的范围内在25°C下。当通过流动方法在esr腔中产生时,α-羟基环丙基甲基自由基经历β裂变,随后进行1,5-氢原子转移以提供烯氧基。与非极性溶剂相比,后者在水中的反应更慢。刚性羟基降三环基自由基(43)可能会由于过渡态的偶极性质而优先发生取代度较低的βγ键的裂变。
    DOI:
    10.1039/p29800001473
  • 作为产物:
    描述:
    (-)-cis-1-carbomethoxy-2-methylcyclohexane 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以83%的产率得到cis-1-hydroxymethyl-2-methylcyclohexane
    参考文献:
    名称:
    基于片段的吡唑并吡啶酮作为JAK1抑制剂的发现,具有出色的亚型选择性。
    摘要:
    在这里,我们报告发现了一系列具有高效力和出色的JAK家族亚型选择性的JAK1选择性激酶抑制剂。选择具有吡唑并吡啶酮核心和JAK1偏倚的片段筛选结果1作为我们基于片段的线索生成工作的起点。选择了两阶段策略,以提高效能和JAK1选择性的双重目的:优化亲脂性核糖口袋靶向的取代基,然后引入各种靶向P环的官能团。结合来自优化的两个阶段的最佳部分,得到化合物40,其显示出优异的效能和选择性。代谢研究在体外和体内具有一起体外安全性评估表明40可能是开发高度亚型选择性JAK1抑制剂的可行先导化合物。
    DOI:
    10.1021/acs.jmedchem.0c00359
点击查看最新优质反应信息

文献信息

  • Oxidation with the “H2O2-managanese(IV) complex-carboxylic acid” reagent
    作者:G. B. Shul'pin、J. R. Lindsay-Smith
    DOI:10.1007/bf02641538
    日期:1998.12
    A carboxylic acid is an obligatory component of the reaction mixture, while acetonitrile or acetone can be used as solvent. The reaction occurs, forming alkyl hydroperoxide, ketone, and alcohol. Substitution at the tertiary carbon atom proceeds more easily than that at the secondary carbon atom, whereas primary C−H bonds are rather inactive. Oxidation of alkanes and alcohols with peroxy acids catalyzed
    复合物 [LMnIV(O)3MnIVL](PF6)2 (1),其中 L 是 1,4 7-三甲基-1,4,7-三氮杂环壬烷,在 H2O2 存在下催化饱和烃的高效立体选择性氧化。羧酸是反应混合物的必需成分,而乙腈或丙酮可用作溶剂。发生反应,形成烷基氢过氧化物、酮和醇。叔碳原子上的取代比仲碳原子上的取代更容易进行,而伯 C-H 键相当不活泼。由配合物 1 催化的烷烃和醇与过氧酸的氧化效率较低。
  • Scope and limitations of the stereoselective homogeneous hydrogenation of methylenecyclohexanols by cationic rhodium complexes
    作者:John M. Brown、Stephen A. Hall
    DOI:10.1016/s0040-4039(01)80167-2
    日期:1984.1
    Homogeneous catalytic hydrogenation of 3-methylenecyclohexanol gives -3-methylcyclohexanol with 98% stereoselectivity. but low selectivity is observed for 2-methylenecyclohexanol and 2-methylenecyclohexanemethanol.
    3-亚甲基环己醇的均相催化加氢得到具有98%立体选择性的-3-甲基环己醇。但是观察到2-亚甲基环己醇和2-亚甲基环己烷甲醇的选择性低。
  • Purine compounds and methods of use thereof
    申请人:Salzman L. Andrew
    公开号:US20070238694A1
    公开(公告)日:2007-10-11
    The invention relates to Purine Compounds; compositions comprising an effective amount of a Purine Compound; and methods for reducing a subject's rate of metabolism or protecting a subject's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, diabetes, a cellular proliferative disorder, a skin disorder, a radiation-induced injury, a wound or an inflammatory disease comprising administering an effective amount of a Purine Compound to a subject in need thereof.
    这项发明涉及嘌呤化合物;包含有效量嘌呤化合物的组合物;以及用于减少受试者代谢率或在心脏停搏期间保护受试者心脏免受心肌损伤,或用于治疗或预防心血管疾病、神经系统紊乱、缺血情况、再灌注损伤、肥胖、消耗性疾病、糖尿病、细胞增殖紊乱、皮肤疾病、辐射诱导损伤、创伤或炎症疾病的方法,包括向需要的受试者施用有效量的嘌呤化合物。
  • Isoxazoline-substituted benzamide compound and pesticide
    申请人:Mita Takeshi
    公开号:US20070066617A1
    公开(公告)日:2007-03-22
    An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof: wherein A 1 , A 2 and A 3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C 1 -C 6 haloalkyl, etc., Y is halogen atm, C 1 -C 6 alkyl, etc., R 1 is C 1 -C 12 alkyl arbitrarily substituted with R 16 , C 3 -C 2 alkenyl, arbitrarily substituted with R 16 is oxygen atom or sulfur atom, —N(R 20 )R 19 , etc., R 2 is hydrogen atom, C 1 -C 4 alkoxy C 1 -C 6 alkyl, etc., R 3 is C 1 -C 6 haloalkyl, etc., R 16 is halogen atom, cyano, phenyl substituted with (Z) p1 , D-1 to D-60, E-1 to E-49, etc., R 19 is phenyl, phenyl substituted with (Z) p1 , etc., R 20 is hydrogen atom, C 1 -C 6 alkyl, etc., Z is halogen atom, nitro, C 1 -C 4 alkoxy, etc., D-1 to D-60 are 5- or 6-membered aromatic heterocyclic rings, E-1 to E-49 are 5- or 6-membered saturated heterocyclic rings, m is an integer of 0 to 5, n is an integer of 0 to 4, p1 is an integer of 1 to 5. The pesticide containing these compounds.
    一种公式(1)所示的异噁唑基取代的苯甲酰胺化合物或其盐: 其中A1,A2和A3独立地为碳原子或氮原子,G为苯环等,X为卤素原子,C1-C6卤代烷基等,Y为卤素原子,C1-C6烷基等,R1是任意取代的C1-C12烷基,或者任意取代的C3-C2烯基,取代基为R16,R16是卤素原子,氰基,苯基取代的(Z)p1,D-1至D-60,E-1至E-49等,R2为氢原子,C1-C4烷氧基C1-C6烷基等,R3为C1-C6卤代烷基等,R19为苯基,苯基取代的(Z)p1等,R20为氢原子,C1-C6烷基等,Z为卤素原子,硝基,C1-C4烷氧基等,D-1至D-60为5-或6-成员芳香杂环环,E-1至E-49为5-或6-成员饱和杂环,m为0至5的整数,n为0至4的整数,p1为1至5的整数。包含这些化合物的杀虫剂。
  • ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE
    申请人:MITA Takeshi
    公开号:US20110251398A1
    公开(公告)日:2011-10-13
    A 3,5-Bis (substituted aryl) substituted isoxazoline compound of formula (2) or a salt thereof: wherein A1 is a carbon atom or nitrogen atom; X1 is selected from the group consisting of a halogen atom, —SF5, C1-C6haloalkyl, hydroxy C1-C6haloalkyl, C1-C6alkoxy C1-C6haloalkyl, C1-C6haloalkoxy C1-C6haloalkyl, C3-C8halocycloalkyl, C1-C6haloalkoxy, C1-C3haloalkoxy C1-C3haloalkoxy, C1-C6haloalkylthio, C1-C6haloalkylsulfinyl and C1-C6haloalkylsulfonyl; X2 is selected from the group consisting of a halogen atom, cyano, nitro, C1-C6alkyl, C1-C6haloalkyl, —OR5, —OSO2R5 and —S(O)rR5; Y is selected from the group consisting of a halogen atom, cyano, nitro, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C6alkylthio, C1-C6haloalkylthio, C1-C6alkylsulfonyl, C1-C6haloalkylsulfonyl, —NHR7 and —N(R7)R6; R is selected from the group consisting of a halogen atom, cyano, nitro, —NH2, halosulfonyloxy, C1-C6alkylsulfonyloxy, C1-C6haloalkylsulfonyloxy, phenylsulfonyloxy, phenylsulfonyloxy substituted with (Z)p1 and —C(O)Ra; m1 is an integer of 0 to 2; n is an integer of 0 or 1; p1 is an integer of 1 to 5; and r is an integer of 0 to 2.
    化合物公式为(2)的3,5-双(取代芳基)取代异噁唑化合物或其盐: 其中,A1为碳原子或氮原子;X1选自卤素原子、—SF5、C1-C6卤代烷基、羟基C1-C6卤代烷基、C1-C6烷氧基C1-C6卤代烷基、C1-C6卤代烷氧基C1-C6卤代烷基、C3-C8卤代环烷基、C1-C6卤代烷氧基、C1-C3卤代烷氧基C1-C3卤代烷氧基、C1-C6卤代烷基硫、C1-C6卤代烷基亚砜和C1-C6卤代烷基磺酰基;X2选自卤素原子、氰基、硝基、C1-C6烷基、C1-C6卤代烷基、—OR5、—OSO2R5和—S(O)rR5;Y选自卤素原子、氰基、硝基、C1-C4烷基、C1-C4卤代烷基、C1-C4烷氧基、C1-C4卤代烷氧基、C1-C6烷基硫、C1-C6卤代烷基硫、C1-C6烷基磺酰基、C1-C6卤代烷基磺酰基、—NHR7和—N(R7)R6;R选自卤素原子、氰基、硝基、—NH2、卤代磺酸酯氧基、C1-C6烷基磺酸酯氧基、C1-C6卤代烷基磺酸酯氧基、苯基磺酸酯氧基、苯基磺酸酯氧基,其取代基为(Z)p1和—C(O)Ra;m1为0至2的整数;n为0或1的整数;p1为1至5的整数;r为0至2的整数。
查看更多